Summary by Moomoo AI
On September 5, 2024, Sir Marc Feldmann filed a Schedule 13G with the United States Securities and Exchange Commission (SEC), indicating a significant ownership stake in 180 Life Sciences Corp. The filing revealed that Feldmann holds 90,532 shares of the company's common stock, which includes options to purchase an additional 20,000 shares. As of the filing date, this represented 8.6% of the company's class of securities. However, by October 17, 2024, his percentage ownership decreased to 4.5%. The filing was made in accordance with Rule 13d-1(b) and Rule 13d-1(c), and Feldmann certified that the shares were not acquired for the purpose of changing or influencing the control of the issuer. Sir Marc Feldmann, a UK and Australian citizen, is known for his contributions to the field of immunology and has a principal business address in London, UK.
